Ginkgo Bioworks (DNA) President Shetty Sells $418K of Stock

Ginkgo Bioworks Holdings, Inc. President & Founder Reshma P. Shetty sold 41,172 shares of the company on October 19, 2026. According to a Form 4 filed with the Securities and Exchange Commission, the transaction was executed at an average price of $10.14 per share, for a total value of about $417,607.60. The stock closed at $10.07 on the day of the trade.

DNA Ginkgo Bioworks Holdings, Inc.

$10.01 ▲ +15.06% year to date

1M 3M YTD

Daily close · Oct 21, 2026

Inside Reshma P. Shetty's Ginkgo Bioworks Trade

The sale reduced Shetty's holdings by 8.32%, cutting her position down to 453,951 shares. The trade took place on the open market and was not part of a pre-arranged Rule 10b5-1 trading plan. This follows prior insider sales at the biotechnology firm earlier in the year, including recent transactions by Chief Financial Officer Steven P. Coen and CEO Jason R Kelly.

Other Institutional Activity in Ginkgo Bioworks

Viking Global Investors, L.P. kept its stake steady at 3,577,128 shares worth about $35.8 million. Erste Asset Management GmbH grew its holdings by 589,193 shares, ending with 2,536,939 shares worth about $25.4 million. BAILLIE GIFFORD & CO held steady with 2,391,649 shares valued at about $23.9 million. Anchorage Capital Group, LLC maintained its position of 1,746,363 shares worth about $17.5 million. Legal & General Group PLC added 7,810 shares, ending with 1,669,419 shares worth about $16.7 million.

Ginkgo Bioworks Holdings, Inc. Stock Down 1.3%

Ginkgo Bioworks shares recently traded around $9.73 as of October 21, 2026, sitting 3.4% below their event-day close. The stock trades above both its 50-day moving average of $8.92 and its 200-day moving average of $8.52. Shares remain well below their 52-week high of $18.22 while trading above their 52-week low of $5.37.

Recent Earnings

Ginkgo Bioworks generated $132.4 million in trailing-twelve-month revenue with a negative earnings per share of $5.06. The firm posted a net profit margin of -219.6% and a return on equity of -59.9%, alongside a year-over-year revenue decline of 48.5%. The company is scheduled to release its next financial update on November 5, 2026.

Insider Buying and Selling at Ginkgo Bioworks Holdings, Inc.

Insiders have active sales history over recent months. Chief Financial Officer Steven P. Coen sold 752 shares on July 17, 330 shares on August 24, and 2,403 shares on October 5. Director Christian O Henry sold 5,000 shares on September 15.

Analysts Set New Price Targets

TD Cowen maintained a hold rating while raising its price target to $11.00 on October 13, following an earlier downgrade to hold with a $9.00 target on August 7. BTIG reiterated a sell rating with a $5.00 price target on September 4. The stock carries a consensus underperform rating and a mean price target of $8.00 across two analyst opinions.

About Ginkgo Bioworks

Headquartered in Boston, Massachusetts, Ginkgo Bioworks builds a platform for cell engineering used across biotechnology applications. The company operates through cell engineering and biosecurity segments to support biological research and development.

Bottom Line

Investors are watching for the upcoming earnings report on November 5, 2026, to gauge operational progress. Form 4 filings provide direct insight into executive share management as the company navigates its current market position.